These trends were most notable in women with estrogen receptor-positive cancers, the researchers note.
上述趋势在雌激素受体阳性乳腺癌患者表现最明显。研究者写道。
According to this new study, yes, it is beneficial to both women who have estrogen receptor positive tumors and estrogen receptor negative tumors.
根据这项新的研究，的确，对雌激素受体阳性肿瘤和雌激素受体阴性肿瘤的妇女都有利。
It would also be important for treatment and prognosis to determine if these cells were estrogen and progesterone receptor positive.
确定这些细胞雌激素与孕激素受体阳性与否对治疗与预后也很重要。
Reporting in Nature Genetics, researchers said genetic variants on chromosome 2 and on chromosome 16 May increase the risk of estrogen-receptor-positive breast cancer.
据《自然遗传学》报道，研究人员宣称2号染色体和16号染色体发生基因变异会增加雌激素受体阳性的乳腺癌发病率。
Comparing the two groups might help explain why some estrogen-receptor-positive breast cancer patients do well with estrogen-lowering drugs and others poorly.
这两种情况肿瘤样本的对比也许可以解释为什么一些雌激素受体阳性乳腺癌患者对降雌激素药物有效而有些却效果很差。
Results The estrogen receptor positive cells were coincided highly with mast cells in morphology and location.
结果：雌激素受体阳性细胞与肥大细胞相似、位置相吻合。
Methods MTT assay and flow cytometer (FCM) assay were used to determine the survival rate and apoptosis of MCF-7 cells, which was estrogen receptor positive in culture.
方法以体外培养雌激素受体阳性细胞MCF - 7为研究对象，采用MTT法和流式细胞术法检测MCF - 7细胞存活率和细胞凋亡。
The relapse-free survival in patients with positive estrogen receptor or progesterone receptor was significantly better than those with negative estrogen receptor or progesterone receptor.
雌激素受体或孕酮受体阳性组病例的无复发，生存率明显优于相应之阴性组病例。
The relapse-free survival in patients with positive estrogen receptor or progesterone receptor was significantly better than those with negative estrogen receptor or progesterone receptor.
雌激素受体或孕酮受体阳性组病例的无复发，生存率明显优于相应之阴性组病例。
应用推荐